The latest information about BioMark Diagnostics to keep you up to date.
BioMark Diagnostics is leading the world in early-stage cancer detection with an oncology focus designed to improve patient outcomes.
The new family of patent granted by USPTO strengthens BioMark’s global intellectual property position in
BIOMARK LATEST RESULTS ACCEPTED FOR PRESENTATION at the American Society of Clinical Oncology (ASCO) Annual
BIOMARK PRESENTS NOVEL LIQUID BIOPSY DATA IN PULMONARY NEUROENDOCRINE TUMORS Vancouver, British Columbia – (March
BIOMARK PROVIDES THIRD QUARTER OPERATIONAL UPDATE AND 2023 Vancouver, British Columbia – (March 1st, 2022)
BIOMARK RECEIVES FUNDING SUPPORTING RESEARCH AND DEVELOPMENT PROJECT FOR CANCER TREATMENT MONITORING Vancouver, British Columbia
BIOMARK ANNOUNCES UPDATE FROM ONGOING CLINICAL TRIAL USING ITS LUNG CANCER LIQUID BIOSPY TEST AS
BIOMARK PROVIDES BUSINESS UPDATE AND SECOND QUARTER Financial RESULTS Vancouver, British Columbia – (November 28,
BIOMARK’s GLIOBLASTOMA Study Published in CANCERS Demonstrates Inhibiting SAT1 Sensitized Cancer Cells Towards Radiation and
THE US PATENT OFFICE GRANTS BIOMARK ADDITIONAL PATENT FOR ITS LIQUID BIOPSY TECHNOLOGY Vancouver, British
No paperwork, no hassle. We keep things digital, easy and regular.
*Zero Spam Policy. You will need to confirm your email address to receive our news to your inbox.
1 604 370 0779
130 3851 Shell Road
Richmond BC
Canada V6X 2W2
Rashid A. Bux (CEO)
[email protected]